Publication: In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides
Issued Date
2009-10-01
Resource Type
ISSN
09248579
Other identifier(s)
2-s2.0-67651225112
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Antimicrobial Agents. Vol.34, No.4 (2009), 309-314
Suggested Citation
Sakawrat Kanthawong, Kamran Nazmi, Surasakdi Wongratanacheewin, Jan G M Bolscher, Vanaporn Wuthiekanun, Suwimol Taweechaisupapong In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides. International Journal of Antimicrobial Agents. Vol.34, No.4 (2009), 309-314. doi:10.1016/j.ijantimicag.2009.05.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/27905
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides
Other Contributor(s)
Abstract
Burkholderia pseudomallei, the causative agent of melioidosis, is intrinsically resistant to many antibiotics, resulting in high mortality rates of 19% in Australia and even 50% in Thailand. Antimicrobial peptides (AMPs) possess potent broad-spectrum bactericidal activities and are regarded as promising therapeutic alternatives in the fight against resistant microorganisms. Moreover, these peptides may also affect inflammation, immune activation and wound healing. In this study, the in vitro activities of 10 AMPs, including histatin 5 and histatin variants, human cathelicidin peptide LL-37 and lactoferrin peptides, against 24 isolates of B. pseudomallei were investigated. The results showed that the antibacterial activities of the individual peptides depended on peptide dose and bacterial isolate. Among the 10 peptides tested, LL-37 exhibited the most effective killing activity. The smooth type A lipopolysaccharide (LPS) phenotype B. pseudomallei appeared to be more susceptible than those expressing the smooth type B LPS and the rough type LPS. Four isolates of B. pseudomallei shown to be resistant to ceftazidime and trimethoprim/sulfamethoxazole were also highly susceptible to LL-37. These data indicate that LL-37 possesses antimicrobial activity against all isolates independent of the LPS phenotype and is therefore a promising peptide to combat B. pseudomallei infections. © 2009 Elsevier B.V. and the International Society of Chemotherapy.